Clinical Updates & Insights


Our clinical updates provide you with timely information about Memorial Sloan Kettering’s new treatment approaches, key clinical trials, and innovations in detecting and treating many cancers.

173 Clinical Updates found
Medical Oncologist Mrinal Gounder, MD
Nirogacestat Improves Outcomes for Patients With Desmoid Tumors
Update: On November 27, 2023, the U.S. Food and Drug Administration approved nirogacestat (Ogsiveo™) for adults with desmoid tumors that cannot be...
physician-scientist Sarat Chandarlapaty, MD, PhD and colleague working in their MSK laboratory.
A Decade of MSK Research Laid Groundwork for Recent Approval of a Targeted Therapy for Metastatic Breast Cancer
You may have heard that the U.S. Food and Drug Administration (FDA) approved elacestrant for postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer on January 27, 2023. In addition, the FDA also approved the Guardant360 CDx assay, a companion liquid biopsy diagnostic device for identifying patients for treatment.
CAR T cell therapy
Allogeneic CAR T Cell Therapy for Multiple Myeloma Shows Promise
A first-in-class allogeneic CAR T cell therapy regimen demonstrated feasibility and acceptable safety with preliminary evidence of efficacy in patients with heavily pretreated multiple myeloma, according to interim results from the phase 1 UNIVERSAL trial (NCT04093596) published recently in Nature Medicine.
Photo of person walking in front of MSK Kids sign
Top Pediatric Cancer Advances at MSK Kids in 2022
Doctors at MSK Kids, the dedicated pediatric service at Memorial Sloan Kettering Cancer Center (MSK), pioneered many advances for pediatric patients in 2022.
Spine Neurosurgeon and Director of Minimally Invasive Spine Oncology at MSK, Ori Barzilai, MD, reviews imaging.
Advancing Spinal Metastasis Care Through Genomic Insights
Building on a legacy of pioneering and validating advances in spinal metastasis care, neurosurgeons and radiation oncologists with the Memorial Sloan Kettering Cancer Center (MSK) Multidisciplinary Spine Tumor Service have been investigating the clinical utility of genomic data as the next frontier for improving patient outcomes.
Person in white lab coat using a pipette with a tiny test tube.
Top Cancer Research Advances at MSK in 2022
Read about some of the biggest scientific discoveries made by MSK researchers in 2022.
(Left to right) Sascha Roth, Luis Diaz, Imtiaz Hussain, Andrea Cercek, Avery Holmes, and Nisha Varughese.
Top Cancer Treatment Advances at MSK in 2022
Doctors at Memorial Sloan Kettering Cancer Center (MSK) pioneered advances in many types of cancer treatment for patients in 2022. Here are some of the most important developments.
Charlotte Ariyan
A Promising Neoadjuvant Combination Immunotherapy for Advanced Melanoma
Neoadjuvant relatlimab and nivolumab achieved high response rates with a favorable safety profile in patients with advanced melanoma, according to initial data from a small clinical trial conducted by researchers at Memorial Sloan Kettering Cancer Center (MSK) and the University of Texas MD Anderson Cancer Center (MD Anderson).
Martin R. Weiser, MD
Updated Clinical Calculator Guides Treatment Plan for Rectal Cancer
Physicians at Memorial Sloan Kettering Cancer Center (MSK) have developed and validated clinical calculators to help patients estimate their likelihood of avoiding a recurrence after treatment for colorectal cancer.
Dr. Motzer reviewing radiology images with nurse.
MSK Research Roundup at ESMO Congress 2022: Practice-Changing Advances in Bladder Cancer, Endometrial Cancer, Renal Cell Carcinoma, Colorectal Cancer, and Breast Cancer
Memorial Sloan Kettering Cancer Center (MSK) researchers presented breakthrough findings for new treatment approaches in several cancer indications at the European Society for Medical Oncology (ESMO) Congress 2022, held September 9 to 13 in Paris. Highlights included clinically meaningful benefits for new treatment strategies in advanced bladder cancer, endometrial cancer, and renal cell carcinoma. Additionally, MSK experts shared their perspectives on previously reported groundbreaking trials of new treatment approaches in colorectal cancer and HER2-low metastatic breast cancer.